Biotechnology · Cambridge, United Kingdom · Founded 2003 · Privately Held (backing)
Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. CellCentric is based in Cambridge, United Kingdom and was founded in 2003. It is valued at about $382 million as of Oct 2026, set by institutional fund marks. It has raised $281 million across 2 recorded rounds; the latest was an $116 million Series C in Apr 2025.
PMV mark · valuation
$382.5M
Oct 2026
Priced at
its later-stage round
Apr 2025
Total raised
$280.5M
Last round
Later Stage VC (Series C)
Apr 2025
No prints on record
No secondary trades in CellCentric shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of CellCentric stock.
